DiaCarta, Inc.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements.

Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

Predicine, a molecular information company based in Silicon Valley, has developed a portfolio of regulated liquid biopsy genomic products to help advance the science of precision medicine in cancer. Its patented GeneRADAR is a RNA + DNA-based liquid biopsy test for early cancer detection, disease monitoring and minimal residual disease assessment. It offers a 600 gene-panel to facilitate biomarker-driven patient enrollment in clinical trials. With its vast data sets and advanced analytics, Predicine partners with 30+ biopharmas to support their clinical trials in US, EU, Australia and China. It operates in US and China.

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Advanced BioScience Laboratories, Inc (ABL) is a leading contract research and manufacturing organization, that partners with our clients to support their vaccine and therapeutic development programs. We offer a unique combination of preclinical and clinical services designed to first address the scientific challenges often encountered during proof-of-concept, and then streamline process development and cGMP production of clinical supply.
ABL can assist with all aspects of production development including, but not limited to:
Basic and translational research
Vaccine and therapeutic product design
Animal models for preclinical evaluation including immunomonitoring , efficacy and potency
Cell line and process development
cGMP manufacture of cell banks and virus banks
cGMP manufacture of clinical supply for protein therapeutics, vaccines and live viral vectors

Ask about our 9,000 sq ft clinical GCLP immunomonitoring space and our vaccine and therapeutic testing services.

With a 50+ year history as a service provider to the life sciences industry, ABL brings a broad technical knowledge base, highly experienced work force, and seasoned project management to every program. Our goal is to become a seamless extension of our clients’ product development group – helping them advance today’s ideas into tomorrow’s medicines. Our history, capabilities and expertise allow ABL to provide solution based services to our clients.